MCID: DBT004
MIFTS: 49

Diabetic Polyneuropathy

Categories: Neuronal diseases

Aliases & Classifications for Diabetic Polyneuropathy

MalaCards integrated aliases for Diabetic Polyneuropathy:

Name: Diabetic Polyneuropathy 12 54 15 32
Diabetes Mellitus with Polyneuropathy 12
Polyneuropathy in Diabetes 12
Diabetic Polyneuropathies 71

Classifications:



External Ids:

Disease Ontology 12 DOID:12785
ICD9CM 34 357.2
MeSH 43 D003929
SNOMED-CT 67 49455004
ICD10 32 G63.2
UMLS 71 C0271680

Summaries for Diabetic Polyneuropathy

MalaCards based summary : Diabetic Polyneuropathy, also known as diabetes mellitus with polyneuropathy, is related to carpal tunnel syndrome and microvascular complications of diabetes 3. An important gene associated with Diabetic Polyneuropathy is AKR1B1 (Aldo-Keto Reductase Family 1 Member B), and among its related pathways/superpathways are PI3K-Akt signaling pathway and MAPK signaling pathway. The drugs Cilostazol and Tadalafil have been mentioned in the context of this disorder. Affiliated tissues include testes, spinal cord and skin, and related phenotypes are behavior/neurological and homeostasis/metabolism

Related Diseases for Diabetic Polyneuropathy

Diseases related to Diabetic Polyneuropathy via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 212)
# Related Disease Score Top Affiliating Genes
1 carpal tunnel syndrome 30.3 VEGFA TAC1 INS
2 microvascular complications of diabetes 3 30.2 INS AKR1B1 AGER
3 osteonecrosis 30.1 VEGFA TNF NOS3
4 autonomic neuropathy 30.1 NTF3 NGF INS AKR1B1
5 diabetic neuropathy 30.0 VEGFA SOD2 NTF3 NGF INS AKR1B1
6 neurogenic arthropathy 29.8 NGF INS
7 uremia 29.7 TNF NOS2 INS
8 diabetic autonomic neuropathy 29.6 NTF3 NGF INS AKR1B1
9 hyperglycemia 29.6 SOD2 NOS3 NOS2 INS APOB AKR1B1
10 polyneuropathy 29.6 VEGFA TWNK TNF POLG NGF INS
11 microvascular complications of diabetes 5 29.5 VEGFA SOD2 NOS3 NOS2 INS AKR1B1
12 impotence 29.5 VEGFA NOS3 NOS2 INS
13 coronary heart disease 1 29.4 NOS3 INS CYBA APOB
14 end stage renal disease 29.4 VEGFA TNF SOD2 NOS3 INS
15 axonal neuropathy 29.2 TWNK POLG ARHGEF10
16 peripheral vascular disease 29.2 VEGFA NOS3 NOS2 INS APOB
17 mononeuropathy 29.2 TNF TAC1 NGF ARHGEF10
18 atherosclerosis susceptibility 28.9 VEGFA TNF NOS3 INS CYBA APOB
19 anxiety 28.9 TNF TAC1 NGF INS
20 vascular disease 28.8 VEGFA TNF NOS3 NOS2 INS APOB
21 diabetes mellitus, type i 28.8 VEGFA TNF SOD2 NOS3 NOS2 INS
22 sleep apnea 28.7 VEGFA TNF TAC1 NOS3 INS APOB
23 sensory peripheral neuropathy 28.7 TAC1 POLG NTF3 NGF ARHGEF10 AKR1B1
24 constipation 28.4 TNF TAC1 NTF3 NOS2 INS AKR1B1
25 neuroblastoma 28.3 VEGFA TNF SOD2 PARP1 NTF3 NGF
26 diabetes mellitus 28.1 VEGFA TNF SOD2 PARP1 NOS3 NOS2
27 alzheimer disease 27.6 TNF SOD2 NTF3 NOS3 NOS2 NGF
28 peripheral nervous system disease 27.4 VEGFA TWNK TNF TAC1 POLG NTF3
29 diabetes mellitus, noninsulin-dependent 27.2 VEGFA TNF TAC1 SOD3 NOS3 NGF
30 neuropathy 10.7
31 hemifacial spasm 10.5 VEGFA NOS3
32 platelet membrane fluidity 10.4 NOS3 NOS2
33 radiation proctitis 10.4 VEGFA TNF
34 soft tissue sarcoma 10.4 VEGFA TNF
35 spotted fever rickettsiosis 10.4 TNF NOS2
36 lymphangiosarcoma 10.4 VEGFA TNF
37 eclampsia 10.4 VEGFA TNF NOS3
38 hepatic vascular disease 10.3 VEGFA TNF NOS3
39 ataxia neuropathy spectrum 10.3 TWNK POLG
40 leukostasis 10.3 VEGFA TNF AGER
41 polg-related disorders 10.3 TWNK POLG
42 optic neuritis 10.3 VEGFA TNF SOD2
43 carotid stenosis 10.3 VEGFA TNF NOS3
44 dystrophinopathies 10.3 TNF NOS2
45 esophagitis 10.3 VEGFA TNF SOD2
46 limb ischemia 10.3 VEGFA TNF NOS3
47 paresthesia 10.3
48 autonomic dysfunction 10.3
49 eales disease 10.3 VEGFA TNF NOS2
50 myotonic cataract 10.3 TWNK POLG

Comorbidity relations with Diabetic Polyneuropathy via Phenotypic Disease Network (PDN): (show all 30)


Acute Cystitis Acute Kidney Failure
Benign Essential Hypertension Bronchitis
Decubitus Ulcer Deficiency Anemia
Dermatomycosis Diabetic Cataract
Esophagitis Familial Atrial Fibrillation
Generalized Atherosclerosis Heart Disease
Hypertension, Essential Hypoglycemia
Hypoglycemic Coma Hypothyroidism
Intermediate Coronary Syndrome Kidney Disease
Microvascular Complications of Diabetes 1 Microvascular Complications of Diabetes 7
Mitral Valve Disease Mononeuritis Multiplex
Mononeuropathy of the Median Nerve, Mild Neurogenic Arthropathy
Neurogenic Bladder Partial Third-Nerve Palsy
Peripheral Vascular Disease Respiratory Failure
Tabes Dorsalis Transient Cerebral Ischemia

Graphical network of the top 20 diseases related to Diabetic Polyneuropathy:



Diseases related to Diabetic Polyneuropathy

Symptoms & Phenotypes for Diabetic Polyneuropathy

MGI Mouse Phenotypes related to Diabetic Polyneuropathy:

45 (show all 19)
# Description MGI Source Accession Score Top Affiliating Genes
1 behavior/neurological MP:0005386 10.45 AAAS AGER AKR1B1 ARHGEF10 CYBA INS
2 homeostasis/metabolism MP:0005376 10.45 AAAS AGER AKR1B1 APOB ARHGEF10 CYBA
3 cardiovascular system MP:0005385 10.44 AGER APOB CYBA INS NGF NOS2
4 growth/size/body region MP:0005378 10.38 AAAS AGER AKR1B1 APOB INS NGF
5 cellular MP:0005384 10.37 AAAS AGER APOB CYBA INS NOS2
6 mortality/aging MP:0010768 10.3 AKR1B1 APOB INS NGF NOS2 NOS3
7 immune system MP:0005387 10.29 AGER APOB CYBA INS NOS2 NOS3
8 nervous system MP:0003631 10.25 AAAS APOB ARHGEF10 CYBA INS NGF
9 muscle MP:0005369 10.21 AGER APOB INS NGF NOS2 NOS3
10 integument MP:0010771 10.19 AGER INS NGF NOS2 PARP1 POLG
11 digestive/alimentary MP:0005381 10.15 AAAS CYBA INS NOS2 NOS3 POLG
12 adipose tissue MP:0005375 10.13 CYBA INS NOS2 NOS3 POLG SOD2
13 liver/biliary system MP:0005370 10.02 APOB INS NOS2 NOS3 SOD2 TNF
14 normal MP:0002873 9.92 AGER INS NGF NOS3 NTF3 SOD3
15 no phenotypic analysis MP:0003012 9.91 INS NGF PARP1 POLG SOD3 TNF
16 renal/urinary system MP:0005367 9.91 AGER AKR1B1 INS NOS2 NOS3 PARP1
17 reproductive system MP:0005389 9.9 AAAS APOB INS NOS2 NOS3 NTF3
18 skeleton MP:0005390 9.65 AGER AKR1B1 CYBA INS NOS2 NOS3
19 vision/eye MP:0005391 9.4 AKR1B1 APOB CYBA INS NGF NOS2

Drugs & Therapeutics for Diabetic Polyneuropathy

Drugs for Diabetic Polyneuropathy (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 85)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Cilostazol Approved, Investigational Phase 4 73963-72-1 2754
2
Tadalafil Approved, Investigational Phase 4 171596-29-5 110635
3 Immunologic Factors Phase 4
4 Antibodies Phase 4
5 Immunoglobulins, Intravenous Phase 4
6 Rho(D) Immune Globulin Phase 4
7 gamma-Globulins Phase 4
8 Immunoglobulins Phase 4
9 Respiratory System Agents Phase 4
10 Phosphodiesterase Inhibitors Phase 4
11 Fibrinolytic Agents Phase 4
12 Phosphodiesterase 3 Inhibitors Phase 4
13 Anti-Asthmatic Agents Phase 4
14 Neuroprotective Agents Phase 4
15 Vasodilator Agents Phase 4
16 Platelet Aggregation Inhibitors Phase 4
17 Bronchodilator Agents Phase 4
18 Linoleate Phase 4
19 Phosphodiesterase 5 Inhibitors Phase 4
20
Capsaicin Approved Phase 2, Phase 3 404-86-4 1548943
21
Methylcobalamin Approved, Investigational Phase 3 13422-55-4
22
Hydroxocobalamin Approved Phase 3 13422-51-0 15589840 11953898
23
Gabapentin Approved, Investigational Phase 3 60142-96-3 3446
24
Tapentadol Approved Phase 3 175591-23-8 9838022
25
Thiamine Approved, Investigational, Nutraceutical, Vet_approved Phase 3 59-43-8, 70-16-6 1130
26
Cyanocobalamin Approved, Nutraceutical Phase 3 68-19-9 44176380
27
Folic acid Approved, Nutraceutical, Vet_approved Phase 3 59-30-3 6037
28
Cobalamin Experimental Phase 3 13408-78-1 6857388
29 Chelating Agents Phase 3
30 Adjuvants, Immunologic Phase 3
31 Benphothiamine Phase 3
32 Dermatologic Agents Phase 2, Phase 3
33 Thiamin Phase 3
34 Excitatory Amino Acid Antagonists Phase 3
35 Vitamin B 12 Phase 3
36 Vitamin B12 Phase 3
37 Adrenergic Agents Phase 3
38 Protective Agents Phase 3
39 Alpha-lipoic Acid Phase 3
40 Micronutrients Phase 3
41 Trace Elements Phase 3
42 Vitamins Phase 3
43 Vitamin B Complex Phase 3
44 Antioxidants Phase 3
45 Folate Phase 3
46 Thioctic Acid Phase 3
47 Nutrients Phase 3
48 Vitamin B9 Phase 3
49
Morphine Approved, Investigational Phase 2 57-27-2 5288826
50
Oxycodone Approved, Illicit, Investigational Phase 2 76-42-6 5284603

Interventional clinical trials:

(show top 50) (show all 79)
# Name Status NCT ID Phase Drugs
1 Treatment With Gamunex 10% Intravenous Immunoglobulin (IVIg) for Patients With Demyelination and Diabetes Mellitus: A Blinded, Placebo-Controlled Crossover Pilot Study Unknown status NCT02372149 Phase 4 10% intravenous immunoglobulin (IVIg);0.9% sodium chloride
2 Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Completed NCT01076478 Phase 4 Cilostazol
3 A 12-week, Multi-center, Randomized, Double-blind, Double Dummy, Parallel Clinical Trial to Compare the Efficacy of γ-linolenic Acid and Thioctic Acid in Patients With Diabetic Neuropathy Completed NCT03914404 Phase 4 γ-linoleic acid and placebo(Thioctic Acid);Thioctic Acid and placebo(γ-linoleic acid)
4 Long Term, Double Blind, Randomized, Placebo Controlled Multi-center Study of FRE.M.S.- Frequency Modulated Neural Stimulation Lorenz Therapy™ in Symptomatic Diabetic Neuropathy Completed NCT01628627 Phase 4
5 Phase IV Study on New Insights in Remodeling of Diabetic Cardiomyopathy: Gender Difference in Intramyocardial, Molecular and Neuroendocrine Assessment in Response to Chronic Inhibition of Cyclic GMP Phosphodiesterase 5A Completed NCT01803828 Phase 4 Tadalafil;Placebo
6 Efficacy, Safety, Tolerability and Pharmacokinetics of Concomitant Administration of Tramadol With Duloxetine or Pregabalin: a Randomized Controlled Flexible-dose Study in Patients With Neuropathic Pain Withdrawn NCT01116531 Phase 4 Tramadol;Duloxetine;Pregabalin
7 Effect of Pioglitazone on Intima Media Thickness, Endothelial Function, and Heart Rate Variability in Patients With Impaired Glucose Tolerance Withdrawn NCT00306826 Phase 4 pioglitazone;simvastatin;pioglitazone + simvastatin
8 Effects of Benfotiamine on Intraepidermal Nerve Fiber Density (IENFD)and Diabetic Neuropathy in Subjects With Sensorimotor Diabetic Polyneuropathy: a Double-blind, Randomized, Placebo-controlled Parallel Group Pilot Study Over 12 Months. Unknown status NCT01868191 Phase 3 Benfotiamine;Placebo for benfotiamine
9 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Diabetic Polyneuropathy (Stage 1 or 2) NATHAN1 A Randomized, Placebo-controlled, Double-blind Multi-centre Trial With 2 Parallel Groups Completed NCT00977483 Phase 3 Thioctic Acid;Placebo
10 A Randomized, Crossover, Double Blinded, Placebo Controlled Trial of Topical Capsaicin in Treatment of Painful Diabetic Neuropathy Completed NCT00993070 Phase 2, Phase 3 Capsaicin;placebo
11 Assessment of Efficacy and Safety of Thioctic Acid in the Oral Treatment of Symptomatic Diabetic Neuropathy (SYDNEY 2) Randomised, Double-Blind,Placebo-Controlled Multicentre Trial With 4 Parallel Groups Completed NCT00328601 Phase 3 Thioctic Acid
12 Neuropathic Pain Treatment Using F0434 vs. Gabapentin in Patients With Chronic Distal Diabetic Polyneuropathy: A Randomized, Controlled, Double-blind Study Completed NCT01263132 Phase 3 F0434;Gabapentin
13 Dietetic and Hygiene Measures in Metabolic Neuropathies: the Neurodiet Study Completed NCT01465620 Phase 3
14 A Randomized-Withdrawal Phase 3 Study Evaluating the Safety and Efficacy of CG5503 Extended Release (ER) in Subjects With Painful Diabetic Peripheral Neuropathy Completed NCT00455520 Phase 3 CG5503;placebo
15 Phase 2 Study for Infrared Thermometry Used by Diabetic Patients at Home Completed NCT00289497 Phase 2, Phase 3
16 Impact of Lipoic Acid Use on Stroke Outcome After Reperfusion Therapy in Patients With Diabetes Recruiting NCT04041167 Phase 3 alpha lipoic acid;Saline
17 Lidorestat (IDD 676) for the Treatment of Diabetic Neuropathy Unknown status NCT00043797 Phase 2 Lidorestat (IDD 676)
18 Phase 2 Study of the NormaTec PCD in the Treatment of Diabetic Peripheral Neuropathy Unknown status NCT01175928 Phase 1, Phase 2
19 Phase IIa Randomized Double-blind Placebo-controlled Study to Evaluate the Effect of Rosuvastatin in Diabetic Polyneuropathy Completed NCT01622777 Phase 2 Rosuvastatin;Placebo
20 A Randomized Phase IIa Trial Evaluating the Safety and Efficacy of a New Centrally Acting Analgesic in Subjects With Pain Due to Diabetic Polyneuropathy Completed NCT00878293 Phase 2 GRT6005;MS Continus®;Placebo
21 Pilot Study to Evaluate Magnetic Marker Imaging on Diabetic Polyneuropathy and Gastroparesis Completed NCT01607684 Phase 2
22 An Exploratory, Randomised, Double-blind, Single-dummy, Placebo Controlled, Parallel Group Study to Demonstrate the Analgesic Efficacy of Oxycodone/Naloxone Prolonged Release Tablets in Addition to Pregabalin Compared to Pregabalin Alone in Opioid-naïve Subjects Treated With Pregabalin Suffering From Moderate to Severe Pain Due to Diabetic Polyneuropathy Completed NCT00944697 Phase 2 Oxycodone Naloxone;Placebo tablets
23 A Study to Investigate the Analgesic Efficacy of AZD2423 Compared With Placebo Completed NCT01201317 Phase 2 AZD2423;AZD2423;Placebo
24 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging, Study to Evaluate the Efficacy and Safety of 3 Doses of TAK-583 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00760955 Phase 2 TAK-583;TAK-583;TAK-583;Placebo
25 A Phase II, Randomized, Double-Blind, Placebo-Controlled, 24-Week Dose Finding Study to Evaluate the Efficacy and Safety of 20mg, 40mg and 80mg of MCC-257 in Patients With Mild to Moderate Diabetic Polyneuropathy Completed NCT00307749 Phase 2 Placebo;MCC-257;MCC-257;MCC-257
26 A Randomized 4-week Phase IIa Trial Evaluating the Efficacy, Safety, and Tolerability of GRT6005, a New Centrally Acting Analgesic, in Subjects With Pain Due to Diabetic Polyneuropathy. Completed NCT01347671 Phase 2 GRT6005;GRT6005;GRT6005;Matching Placebo
27 A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of Three Doses of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Completed NCT00229437 Phase 2 TAK-128;TAK-128;TAK-128;Placebo
28 A Multicenter, Randomized, Double-Blind, Placebo and Active Controlled Study Comparing the Analgesic Efficacy and Safety of ABT-639 to Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT01345045 Phase 2 ABT-639;pregabalin;Placebo
29 A Phase 2b Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderately Severe Diabetic Neuropathy Completed NCT01079325 Phase 2 SB-509
30 A Global, Multicenter, Randomized, Double-Blind Placebo Controlled Study Comparing the Safety and Efficacy of ABT-894, Duloxetine and Placebo in Subjects With Diabetic Neuropathic Pain Completed NCT00507936 Phase 2 ABT-894;ABT-894;ABT-894;placebo;Duloxetine
31 A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Moderate to Severe Diabetic Neuropathy and Unmeasurable Nerve Conduction Velocity Completed NCT00476931 Phase 2
32 A Safety and Tolerability Study of Mexiletine in Patients With Sporadic Amyotrophic Lateral Sclerosis (SALS) Completed NCT01849770 Phase 2 Mexiletine;Placebo
33 A Phase 2 Repeat Dosing Clinical Trial of SB-509 in Subjects With Diabetic Neuropathy Completed NCT00406458 Phase 2 SB-509
34 A Phase 2 Study of Stem-Cell-Mobilization in Subjects With Diabetic Neuropathy Receiving SB-509 Completed NCT00665145 Phase 2 SB-509;SB-509;Placebo;SB-509
35 Ezetimibe/Simvastatin and Rosuvastatin for Oxidative Stress and Mitochondrial Function in Diabetic Polyneuropathy: a Randomized, Double Blinded, Placebo Controlled Clinical Trial Completed NCT02129231 Phase 2 calcined magnesia;Ezetimibe/simvastatin;Rosuvastatin
36 A Phase IIa Dose Escalation Pilot Study to Investigate the Safety and Tolerability of Intranasal Insulin in Subjects With Diabetic Polyneuropathy. Completed NCT01469559 Phase 2 Novolin Toronto insulin;Normal saline
37 Effect of Mexiletine on Cortical Hyperexcitability in Sporadic Amyotrophic Lateral Sclerosis (SALS) Completed NCT02781454 Phase 2 Mexiletine;Placebo
38 Nicotinamide Riboside in Diabetic Polyneuropathy Recruiting NCT03685253 Phase 1, Phase 2 Niagen;Placebo
39 A Phase II Randomized, Double-Blind, Placebo-Controlled, Cross-Over Study Investigating the Safety and Efficacy of Omnitram in Diabetic Neuropathy Active, not recruiting NCT03664921 Phase 2 Omnitram Oral Tablet;Placebo Oral Tablet
40 ASP 8825 Phase II Study—A Double- Blind, Placebo- Controlled Study in Patients With Painful Diabetic Polyneuropathy Terminated NCT00508430 Phase 2 ASP8825;Placebo
41 An Open-Label, Multi-Center Study to Evaluate the Safety of Long-Term Administration of TAK-128 in Subjects With Mild to Moderate Diabetic Peripheral Neuropathy Terminated NCT00756041 Phase 2 TAK-128
42 A Phase 2 Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel Group, Proof Of Concept Study Of The Analgesic Effects Of Tanezumab In Adult Patients With Diabetic Peripheral Neuropathy Terminated NCT01087203 Phase 2
43 A Randomized, Open-label, Balanced, Two-treatment, Four-period, Two-sequence, Single Dose, Fully Replicate, Crossover, Oral Bioequivalence Study of Alpha Lipoic Acid 600 mg HR Film Coated Tablets of Llko Ilac San. Ve Tic. A.S., Turkey and Thioctacid (Alpha Lipoic Acid) 600 mg HR Film Coated Tablets of Meda Pharma GmbH& CO .KG, Germany in 28 Healthy, Adult, Human Subjects Under Fasting Conditions. Completed NCT04214665 Phase 1 Alpha Lipoic acid 600 mg HR film coated tablets
44 A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 150 mg and GLA5PR GLARS-NF3 Tablet 150 mg in Healthy Volunteers Completed NCT02955472 Phase 1 GLA5PR GLARS-NF3 tablet 150mg;GLA5PR GLARS-NF1 tablet 150mg
45 A Randomized, Open-label, Single Dose, Crossover Phase 1 Study to Compare the Pharmacokinetic Characteristics of GLA5PR GLARS-NF1 Tablet 300 mg and GLA5PR GLARS-NF3 Tablet 300 mg in Healthy Volunteers Completed NCT02952937 Phase 1 GLA5PR GLARS-NF3 tablet 300mg;GLA5PR GLARS-NF1 tablet 300mg
46 A Phase 1b, Randomized, Double-Blind, Parallel, Placebo- and Active-Controlled, Pharmacodynamic Study of BIIB095 and BIIB074 in Healthy Participants and Participants With Painful Diabetic Polyneuropathy Not yet recruiting NCT04106050 Phase 1 BIIB095;BIIB074;Placebo;Lidocaine
47 Functional Imaging of the Therapeutic Effect of Pregabalin in Treatment for Neuropathic Pain in Patients With Diabetic Polyneuropathy Using Proton MR Spectroscopy Unknown status NCT01180608
48 A Prospective Study of High-resolution Ultrasonography in Examination of Lower Extremity Peripheral Nerves in Patients With Compression Neuropathies and in Healthy Controls. Unknown status NCT03560505
49 Neurotrophic Factors in Cerebrospinal Fluid in Diabetic Patients With Polyneuropathy Unknown status NCT01718015
50 Effect of Spinal Cord Stimulation in Painful Diabetic Polyneuropathy: a Multicenter Randomised Controlled Trial (PDP Study) Unknown status NCT01162993

Search NIH Clinical Center for Diabetic Polyneuropathy

Genetic Tests for Diabetic Polyneuropathy

Anatomical Context for Diabetic Polyneuropathy

MalaCards organs/tissues related to Diabetic Polyneuropathy:

40
Testes, Spinal Cord, Skin, Endothelial, Pancreas, Heart, Bone

Publications for Diabetic Polyneuropathy

Articles related to Diabetic Polyneuropathy:

(show top 50) (show all 1127)
# Title Authors PMID Year
1
Aldose reductase inhibitors for the treatment of diabetic polyneuropathy. 61 54
17943821 2007
2
Nerve growth factor for the treatment of diabetic neuropathy: what went wrong, what went right, and what does the future hold? 61 54
12198818 2002
3
[Nerve growth factor (NGF) in treatment of diabetic polyneuropathy. One hope less?]. 54 61
11433707 2001
4
Effect of NGF and neurotrophin-3 treatment on experimental diabetic autonomic neuropathy. 61 54
11245210 2001
5
Biological actions of nerve growth factor in the peripheral nervous system. 61 54
10023124 1999
6
Neurotrophin-3 is increased in skin in human diabetic neuropathy. 54 61
9728960 1998
7
[Effects of the aldose reductase inhibitor on diabetic polyneuropathy--the efficacy of F wave measurement]. 54 61
9789304 1998
8
The role of endogenous nerve growth factor in human diabetic neuropathy. 61 54
8640566 1996
9
Non-coding RNA regulators of diabetic polyneuropathy. 61
32454150 2020
10
Diabetic polyneuropathy: Bridging the translational gap. 61
32573914 2020
11
Electrodiagnostic accuracy in polyneuropathies: supervised learning algorithms as a tool for practitioners. 61
32518996 2020
12
Metabolic Factors, Lifestyle Habits, and Possible Polyneuropathy in Early Type 2 Diabetes: A Nationwide Study of 5,249 Patients in the Danish Centre for Strategic Research in Type 2 Diabetes (DD2) Cohort. 61
32295810 2020
13
An exploratory study of relationship between lower-limb muscle mass and diabetic polyneuropathy in patients with type 2 diabetes. 61
32550177 2020
14
Transplantation of human dental pulp stem cells ameliorates diabetic polyneuropathy in streptozotocin-induced diabetic nude mice: the role of angiogenic and neurotrophic factors. 61
32546222 2020
15
Transcranial direct current stimulation improves quality of life and physical fitness in diabetic polyneuropathy: a pilot double blind randomized controlled trial. 61
32550183 2020
16
Beneficial effects of combination therapy of canagliflozin and teneligliptin on diabetic polyneuropathy and β-cell volume density in spontaneously type 2 diabetic Goto-Kakizaki rats. 61
32302619 2020
17
[Recommendations of the second update of the LONTS guidelines : Long-term opioid therapy for chronic noncancer pain]. 61
32377861 2020
18
Evaluation of spatio-temporal gait parameters and gait symmetry in diabetic polyneuropathic patients with burn injury: A pilot study. 61
31843285 2020
19
Application value of conventional ultrasound and real-time shear wave elastography in patients with type 2 diabetic polyneuropathy. 61
32268245 2020
20
Characterization of experimental diabetic neuropathy using multicontrast magnetic resonance neurography at ultra high field strength. 61
32371885 2020
21
Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. 61
32276788 2020
22
Determinants of Treatment Response in Painful Diabetic Peripheral Neuropathy. A Combined Deep Sensory Phenotyping and Multi-modal Brain Magnetic Resonance Imaging Study. 61
32471808 2020
23
Expression study of candidate miRNAs and evaluation of their potential use as biomarkers of diabetic neuropathy. 61
32400192 2020
24
Relationship between the Diabetic Polyneuropathy Index and the Neurological Findings of Diabetic Polyneuropathy. 61
32448837 2020
25
Neurogenic tissue nanotransfection in the management of cutaneous diabetic polyneuropathy. 61
32422219 2020
26
Human adipose-derived mesenchymal stem cell-conditioned medium ameliorates polyneuropathy and foot ulceration in diabetic BKS db/db mice. 61
32357914 2020
27
Diabetic polyneuropathy and the risk of developing carpal tunnel syndrome: A nationwide, population-based study. 61
32329529 2020
28
Troponin T Parallels Structural Nerve Damage in Type 2 Diabetes: A Cross-sectional Study Using Magnetic Resonance Neurography. 61
31974140 2020
29
Beneficial effects of nano-curcumin supplement on depression and anxiety in diabetic patients with peripheral neuropathy: A randomized, double-blind, placebo-controlled clinical trial. 61
31788880 2020
30
Factors associated with diabetic polyneuropathy-related sensory symptoms and signs in patients with polyneuropathy: A cross-sectional Japanese study (JDDM 52) using a non-linear model. 61
31314173 2020
31
High-Dose Intravenous Immunoglobulin Is Effective in Painful Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled, Multicenter Trial. 61
31904855 2020
32
High-Dose Intravenous Immunoglobulin Is Effective Diabetic Polyneuropathy Resistant to Conventional Treatments. Results of a Double-Blind, Randomized, Placebo-Controlled Trial: Comments. 61
32196108 2020
33
Diabetic polyneuropathy and pain, prevalence, and patient characteristics: a cross-sectional questionnaire study of 5,514 patients with recently diagnosed type 2 diabetes. 61
31693539 2020
34
Understanding Diabetic Neuropathy-From Subclinical Nerve Lesions to Severe Nerve Fiber Deficits: A Cross-Sectional Study in Patients With Type 2 Diabetes and Healthy Control Subjects. 61
31826867 2020
35
Treating Pain in Diabetic Neuropathy: Current and Developmental Drugs. 61
32040849 2020
36
Treatment of painful polyneuropathies of diabetic and other origins with 10 kHz SCS: a case series. 61
32073352 2020
37
The diagnostic usefulness of the combined COMPASS 31 questionnaire and electrochemical skin conductance for diabetic cardiovascular autonomic neuropathy and diabetic polyneuropathy. 61
31985124 2020
38
Microangiopathy: Is it relevant to wound healing in diabetic foot disease? 61
31845461 2020
39
[Diabetic polyneuropathy]. 61
32086529 2020
40
Dorsal Root Ganglion Stimulation in Experimental Painful Diabetic Polyneuropathy: Delayed Wash-Out of Pain Relief After Low-Frequency (1Hz) Stimulation. 61
31524325 2020
41
Expressions of spinal microglia activation, BDNF, and DREAM proteins correlated with formalin-induced nociceptive responses in painful and painless diabetic neuropathy rats. 61
31902597 2020
42
Regional differences in cell-mediated immunity in people with diabetic peripheral neuropathy. 61
31557355 2020
43
Structural Nerve Remodeling at 3-T MR Neurography Differs between Painful and Painless Diabetic Polyneuropathy in Type 1 or 2 Diabetes. 61
31891321 2020
44
Meta-analysis comparing placebo responses in clinical trials of painful HIV-associated sensory neuropathy and diabetic polyneuropathy. 61
32106088 2020
45
Dorsal Root Ganglion Stimulation as a Potentially Effective Treatment for Painful Hereditary and Idiopathic Axonal Polyneuropathy: A Retrospective Case Series. 61
30762923 2020
46
Effect of an educational booklet for prevention and treatment of foot musculoskeletal dysfunctions in people with diabetic neuropathy: the FOotCAre (FOCA) trial II, a study protocol of a randomized controlled trial. 61
32054510 2020
47
Secreted factors from cultured dental pulp stem cells promoted neurite outgrowth of dorsal root ganglion neurons and ameliorated neural functions in streptozotocin-induced diabetic mice. 61
31144464 2020
48
Mechanism of dorsal root ganglion stimulation for pain relief in painful diabetic polyneuropathy is not dependent on GABA release in the dorsal horn of the spinal cord. 61
31334605 2020
49
Therapeutic efficacy of arginine-rich exenatide on diabetic neuropathy in rats. 61
31794708 2020
50
Lumos for the long trail: Strategies for clinical diagnosis and severity staging for diabetic polyneuropathy and future directions. 61
31677343 2020

Variations for Diabetic Polyneuropathy

Expression for Diabetic Polyneuropathy

Search GEO for disease gene expression data for Diabetic Polyneuropathy.

Pathways for Diabetic Polyneuropathy

Pathways related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
12.81 VEGFA TNF NTF3 NOS3 NGF INS
2 12.61 VEGFA TNF NTF3 NGF INS
3
Show member pathways
12.33 NOS3 NOS2 INS CYBA
4 11.97 VEGFA TNF TAC1 NGF
5 11.88 VEGFA TNF NOS3 CYBA
6
Show member pathways
11.69 TNF SOD3 SOD2 INS APOB
7
Show member pathways
11.66 TNF NTF3 NGF
8 11.66 VEGFA NOS3 NOS2 INS
9 11.63 VEGFA NTF3 NGF
10 11.56 VEGFA TNF NOS3 AGER
11
Show member pathways
11.5 VEGFA TNF NOS2
12
Show member pathways
11.43 SOD3 SOD2 CYBA
13 11.33 TNF APOB AGER
14 11.07 SOD3 SOD2 CYBA
15 10.99 NOS3 NOS2 AKR1B1
16 10.74 NOS3 NOS2 INS AGER
17 10.71 NOS3 NOS2 CYBA
18 10.69 NOS3 NOS2
19 10.44 NOS3 NOS2

GO Terms for Diabetic Polyneuropathy

Cellular components related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 extracellular region GO:0005576 9.97 VEGFA TNF TAC1 SOD3 NTF3 NGF
2 extracellular space GO:0005615 9.81 VEGFA TNF TAC1 SOD3 NTF3 NGF
3 cell GO:0005623 9.8 TWNK TAC1 POLG NOS3 NOS2 CYBA
4 vesicle membrane GO:0012506 9.13 NOS3 NOS2 APOB
5 endosome lumen GO:0031904 8.8 NGF INS APOB

Biological processes related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

(show all 29)
# Name GO ID Score Top Affiliating Genes
1 oxidation-reduction process GO:0055114 9.97 SOD3 SOD2 NOS3 NOS2 CYBA AKR1B1
2 positive regulation of cell migration GO:0030335 9.9 VEGFA SOD2 NTF3 INS
3 inflammatory response GO:0006954 9.88 TNF TAC1 NOS2 CYBA AGER
4 positive regulation of gene expression GO:0010628 9.88 VEGFA TNF NOS3 NGF INS APOB
5 mitochondrion organization GO:0007005 9.82 TWNK PARP1 NOS3
6 response to organic substance GO:0010033 9.79 TNF APOB AKR1B1
7 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.79 TNF NTF3 INS
8 cell redox homeostasis GO:0045454 9.76 NOS3 NOS2 CYBA
9 response to lipopolysaccharide GO:0032496 9.76 TAC1 NOS3 NOS2 APOB
10 negative regulation of cysteine-type endopeptidase activity involved in apoptotic process GO:0043154 9.75 VEGFA TNF NGF
11 cellular response to glucose stimulus GO:0071333 9.73 TWNK POLG CYBA
12 regulation of blood pressure GO:0008217 9.72 TAC1 SOD2 NOS3
13 positive regulation of smooth muscle cell proliferation GO:0048661 9.7 TNF CYBA AKR1B1
14 response to hormone GO:0009725 9.69 TAC1 NOS3 NOS2
15 cellular response to oxidative stress GO:0034599 9.67 SOD3 SOD2 PARP1 CYBA
16 negative regulation of oxidative stress-induced intrinsic apoptotic signaling pathway GO:1902176 9.64 SOD2 INS
17 positive regulation of chemokine biosynthetic process GO:0045080 9.63 TNF AGER
18 nerve growth factor signaling pathway GO:0038180 9.63 NTF3 NGF
19 nitric oxide biosynthetic process GO:0006809 9.62 NOS3 NOS2
20 positive regulation of peptidyl-serine phosphorylation GO:0033138 9.62 VEGFA TNF NTF3 NGF
21 positive regulation of guanylate cyclase activity GO:0031284 9.61 NOS3 NOS2
22 mitochondrial DNA replication GO:0006264 9.59 TWNK POLG
23 positive regulation of interleukin-1 beta biosynthetic process GO:0050725 9.57 TNF AGER
24 response to hypoxia GO:0001666 9.55 VEGFA SOD3 NOS2 CYBA AGER
25 arginine catabolic process GO:0006527 9.54 NOS3 NOS2
26 response to aldosterone GO:1904044 9.43 PARP1 CYBA
27 induction of positive chemotaxis GO:0050930 9.43 VEGFA NTF3 AGER
28 removal of superoxide radicals GO:0019430 9.13 SOD3 SOD2 NOS3
29 superoxide metabolic process GO:0006801 8.92 SOD3 SOD2 NOS2 CYBA

Molecular functions related to Diabetic Polyneuropathy according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 identical protein binding GO:0042802 10 VEGFA TWNK TNF SOD2 PARP1 INS
2 oxidoreductase activity GO:0016491 9.63 SOD3 SOD2 NOS3 NOS2 CYBA AKR1B1
3 arginine binding GO:0034618 9.43 NOS3 NOS2
4 superoxide dismutase activity GO:0004784 9.4 SOD3 SOD2
5 NADPH-hemoprotein reductase activity GO:0003958 9.37 NOS3 NOS2
6 nerve growth factor receptor binding GO:0005163 9.32 NTF3 NGF
7 tetrahydrobiopterin binding GO:0034617 9.26 NOS3 NOS2
8 nitric-oxide synthase activity GO:0004517 8.96 NOS3 NOS2
9 protease binding GO:0002020 8.92 TWNK TNF POLG INS

Sources for Diabetic Polyneuropathy

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....